Last 431.30 INR
Change Today 0.00 / 0.00%
Volume 0.0
ALPM On Other Exchanges
Symbol
Exchange
Natl India
As of 6:05 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

alembic pharmaceuticals ltd (ALPM) Snapshot

Open
424.10
Previous Close
422.05
Day High
433.75
Day Low
422.75
52 Week High
01/27/15 - 494.65
52 Week Low
05/19/14 - 227.00
Market Cap
81.3B
Average Volume 10 Days
281.0K
EPS TTM
12.49
Shares Outstanding
188.5M
EX-Date
07/17/14
P/E TM
34.5x
Dividend
3.00
Dividend Yield
0.70%
Current Stock Chart for ALEMBIC PHARMACEUTICALS LTD (ALPM)

Related News

No related news articles were found.

alembic pharmaceuticals ltd (ALPM) Related Businessweek News

No Related Businessweek News Found

alembic pharmaceuticals ltd (ALPM) Details

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and Intermediates in India and internationally. The company operates in three segments: International Generics, Branded Formulations, and Active Pharmaceutical Ingredients. It offers active pharmaceutical ingredients for anti-infective, cardio-vascular, musculoskeletal, erectile dysfunction, and gastro-intestinal products. The company also provides bulk pharma chemicals, including phosgene gas and phosgene based specialty chemicals/intermediates for use in pesticides, pharmaceuticals, dyes, plastics, perfumeries, etc.; and drug intermediates, specialty chemicals, and fine chemicals, as well as is engaged in contract manufacturing and custom synthesis activities. In addition, it offers finished dosage formulations for various therapeutic areas, including anti-infective, cough and cold, cardiovascular, and oral anti-diabetics; herbal nutraceuticals; veterinary products; and contract/collaborated research services. The company was founded in 1907 and is headquartered in Vadodara, India.

Founded in 1907

alembic pharmaceuticals ltd (ALPM) Top Compensated Officers

Chairman and Managing Director
Total Annual Compensation: 30.0M
Chief Financial Officer, Director of Finance ...
Total Annual Compensation: 19.5M
President of International Business, Executiv...
Total Annual Compensation: 34.6M
President of Branded Formulations Business an...
Total Annual Compensation: 33.8M
Compensation as of Fiscal Year 2014.

alembic pharmaceuticals ltd (ALPM) Key Developments

Alembic Pharmaceuticals Appoints Archana Hingorani as Independent Additional Director

Alembic Pharmaceuticals Ltd. in its board meeting held on February 04, 2015, has appointed Dr. (Ms.) Archana Hingorani as an Additional Director (Independent Director) of the Company.

Alembic Pharmaceuticals Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Alembic Pharmaceuticals Limited reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 5,011.9 million compared to INR 4,758.2 million a year ago. Profit from operations before other income interest depreciation and exceptional items was INR 1,055.8 million compared to INR 1,031.8 million a year ago. Net profit from ordinary activities before tax was INR 933.2 million compared to INR 897.8 million a year ago. Net profit from ordinary activities after tax was INR 739.9 million compared to INR 678.4 million a year ago. Basic and diluted earnings per share were INR 3.92 compared to INR 3.60 a year ago. For the nine months, on standalone basis, the company reported net sales/income from operations of INR 15,229.1 million compared to INR 13,868.9 million a year ago. Profit from operations before other income interest depreciation and exceptional items was INR 3,137.9 million compared to INR 2,723.7 million a year ago. Net profit from ordinary activities before tax was INR 2,773.4 million compared to INR 2,357.7 million a year ago. Net profit from ordinary activities after tax was INR 2,195.2 million compared to INR 1,811.4 million a year ago. Basic and diluted earnings per share were INR 11.64 compared to INR 9.61 a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 5,109.5 million compared to INR 4,848.7 million a year ago. Profit from operations before other income interest depreciation and exceptional items was INR 1,024.8 million compared to INR 1,022.3 million a year ago. Net profit from ordinary activities before tax was INR 899.8 million compared to INR 808.3 million a year ago. Net profit from ordinary activities after tax was INR 706.5 million compared to INR 659.3 million a year ago. Basic and diluted earnings per share were INR 3.75 compared to INR 3.50 a year ago. EBITDA was INR 1,024.8 million compared to INR 1,022.3 million a year ago. For the nine months, on consolidated basis, the company reported net sales/income from operations of INR 15,508.5 million compared to INR 13,973.7 million a year ago. Profit from operations before other income interest depreciation and exceptional items was INR 3,074.1 million compared to INR 2,664.2 million a year ago. Net profit from ordinary activities before tax was INR 2,706.0 million compared to INR 2,298.2 million a year ago. Net profit from ordinary activities after tax was INR 2,125.6 million compared to INR 1,742.1 million a year ago. Basic and diluted earnings per share were INR 11.28 compared to INR 9.24 a year ago. EBITDA was INR 3,074.1 million compared to INR 2,664.2 million a year ago.

Alembic Pharmaceuticals Limited, Q3 2015 Earnings Call, Feb 04, 2015

Alembic Pharmaceuticals Limited, Q3 2015 Earnings Call, Feb 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPM:IN 431.30 INR 0.00

ALPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALPM.
View Industry Companies
 

Industry Analysis

ALPM

Industry Average

Valuation ALPM Industry Range
Price/Earnings 29.4x
Price/Sales 4.0x
Price/Book 9.9x
Price/Cash Flow 25.3x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEMBIC PHARMACEUTICALS LTD, please visit www.alembic-india.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.